Dataset Information


Drug Repurposing for Paracoccidioidomycosis Through a Computational Chemogenomics Framework.

ABSTRACT: Paracoccidioidomycosis (PCM) is the most prevalent endemic mycosis in Latin America. The disease is caused by fungi of the genus Paracoccidioides and mainly affects low-income rural workers after inhalation of fungal conidia suspended in the air. The current arsenal of chemotherapeutic agents requires long-term administration protocols. In addition, chemotherapy is related to a significantly increased frequency of disease relapse, high toxicity, and incomplete elimination of the fungus. Due to the limitations of current anti-PCM drugs, we developed a computational drug repurposing-chemogenomics approach to identify approved drugs or drug candidates in clinical trials with anti-PCM activity. In contrast to the one-drug-one-target paradigm, our chemogenomics approach attempts to predict interactions between drugs, and Paracoccidioides protein targets. To achieve this goal, we designed a workflow with the following steps: (a) compilation and preparation of Paracoccidioides spp. genome data; (b) identification of orthologous proteins among the isolates; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Paracoccidioides essential targets using validated genes from Saccharomyces cerevisiae; (e) homology modeling and molecular docking studies; and (f) experimental validation of selected candidates. We prioritized 14 compounds. Two antineoplastic drug candidates (vistusertib and BGT-226) predicted to be inhibitors of phosphatidylinositol 3-kinase TOR2 showed antifungal activity at low micromolar concentrations (<10 ?M). Four antifungal azole drugs (bifonazole, luliconazole, butoconazole, and sertaconazole) showed antifungal activity at low nanomolar concentrations, validating our methodology. The results suggest our strategy for predicting new anti-PCM drugs is useful. Finally, we could recommend hit-to-lead optimization studies to improve potency and selectivity, as well as pharmaceutical formulations to improve oral bioavailability of the antifungal azoles identified.

SUBMITTER: de Oliveira AA 

PROVIDER: S-EPMC6581699 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5923135 | BioStudies
2016-01-01 | S-EPMC4703379 | BioStudies
2015-01-01 | S-EPMC4483234 | BioStudies
2019-01-01 | S-EPMC7015227 | BioStudies
2017-01-01 | S-EPMC5655049 | BioStudies
2015-01-01 | S-EPMC4646694 | BioStudies
2015-01-01 | S-EPMC4471430 | BioStudies
2014-01-01 | S-EPMC4181444 | BioStudies
2018-01-01 | S-EPMC5923147 | BioStudies
2020-01-01 | S-EPMC7078656 | BioStudies